Deputy Director for Clinical and Translational Research
Chair and Blomeyer Professor of Hematology and Oncology
co-Director, Cancer Drug Discovery, Development, and Delivery Program
Professor of Otolaryngology & Medicine and Pharmacology,
Chief Medical Officer at Winship Cancer Institute
Emory University
Dr. Khuri is a clinician/researcher who focuses on developing novel targeted agents to treat and prevent cancer, with an emphasis on lung cancer. In the interview, Dr. Khuri discusses his work on the development of a drug that would target a process (called farneylation) that helps to activate a set of oncogenes.
Interview Questions
About Dr. Khuri
(Time:
11sec
)
What are small molecule inhibitors?
(Time:
1min
1sec
)
In your research, do you focus on treatment or prevention?
(Time:
40sec
)
What is the function of farnesyltransferase and how is it related to cancer?
(Time:
2min
21sec
)
How do farnesyltransferase inhibitors (FTI) work?
(Time:
29sec
)
At what stage is your research on farnesyltransferase inhibitors?
(Time:
1min
3sec
)
How do you target FTIs to cancer cells?
(Time:
1min
3sec
)
What is an oncogene?
(Time:
53sec
)
What is the future of FTI?
(Time:
1min
59sec
)
How does FTI treatment differ from chemotherapy?
(Time:
1min
21sec
)
What led to your focus on prevention?
(Time:
1min
47sec
)
What are retinoids?
(Time:
1min
34sec
)
Can you describe more about the research team at Winship Cancer Institute?
(Time:
1min
9sec
)
Top